AUA2024: Prostate cancer highlights

In this EAU podcast, UROONCO chief editor Dr. Giancarlo Marra (IT) interviews Prof. David Penson (US) on the prostate cancer highlights that were recently presented at the American Urological Association Annual Meeting (AUA2024). Prof. Penson is the AUA Secretary General and Chair of Urology Department at Vanderbilt, Nashville, Tennessee (US).

Published Sun, 26 May 2024
PodcastProstate CancerAUA 2024

This expert discussion starts with the highlights of the P2 programme session, a new session focused on practice changing paradigm shifting research.

Trials include:

i) HIFI, a non-inferiority, prospective, non-randomised, nationwide study performed in 46 French centres comparing HIFU vs RP;
ii) The Next Generation Trial, a phase II prospective validating paired-cohort trial assessing 18F-PSMA1007 PET/CT and mpMRI for locoregional staging of prostate cancer, with final histopathology as the gold standard comparator;
iii) IN APA-RP: a multicentre, open-label, single-arm, Phase 2 study conducted at 27 US urologic practices, focusing on pts with high risk localised PCa who had undergone RP were treated with apalutamide (240 mg; once daily) and ADT for 12 cycles (1 cycle [28 days]).

Finally, Prof. Penson highlights the session of ongoing clinical trials including studies on neoadjuvant enzalutamide, hood technique versus standard radical prostatectomy and transperineal versus transrectal prostate biopsies.

Dr. Marra was able to do this interview during Prof. Penson's visiting professorship at the Molinette Hospital, University of Turin (IT).

To keep update on prostate cancer developments, go to the UROONCO Prostate Cancer Educational Platform.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, Google Podcasts.

Contact our organiser